Sanofi acquires rights to develop and commercialize Aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
In 2020, CORXEL acquired the rights to develop and commercialize aficamten in Greater China
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
The company will receive an upfront payment of Euro 100 million (Rs. 880 crores) for product development and site approval from European authorities
The technical program will run in four sessions and a panel discussion on “Challenges in translation of medical technologies”
The transaction is expected to result in approximately $175 million to support further development of IMG-007
Divestment is part of BASF’s strategic portfolio optimization
Exploring new opportunities within the fast-growing market of microfluidics
FDC Ltd has received final approval from USFDA for the company's Abbreviated New Drug Application (ANDA) for Cefixime 400 mg Tablets
Subscribe To Our Newsletter & Stay Updated